News

Covid-X Open Call to defeat COVID-19/Corona clinical challenges

Published on | 4 years ago

Programmes ICT Health

COVID-X, an exclusive acceleration program funded by the European Union to defeat COVID-19 clinical challenges through the power of data, has launched the Open Call #1 for European Tech Companies with outstanding Data Technology solutions that can overcome COVID-19 clinical challenges and save lives. This Open Call is also addressed for healthcare providers dealing with coronavirus patients and validating the solutions in real care environments. 

Funding: 100.000€ (single player) to validate data solutions with a clinical partner - 150.000€ (team players) to validate the solution (tech companies and healthcare providers)

Deadline: 27.01.2021

All details on www.covid-x.eu 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1743 articles available search in articles 

Testimonial

image of SAPHIRe - Securing the Adoption of Personalised Medicin in Regions

SAPHIRe - Securing the Adoption of Personalised Medicin in Regions

The Department of Economy, Science and Innovation of the Flemish government coordinates the Horizon 2020 Coordination and Support Action SAPHIRe, which started on 1 December 2018. The aim of the project is to secure the adoption of personalised medicine in all European regions, including sparsely populated and remote regions and regions with different innovation capacities. 

The activities of SAPHIRe are complementary to the smart specialisation partnership on personalised medicine – S3P4PM, which is also coordinated by the Department of Economy, Science and Innovation.